Back to Search Start Over

Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials.

Authors :
Al-Shahi Salman, R.
Stephen, J.
Tierney, J.F.
Lewis, Steff C.
Newby, D.E.
Parry-Jones, A.R.
White, P.M.
Connolly, S.J.
Benavente, O.R.
Dowlatshahi, D.
Cordonnier, C.
Viscoli, C.M.
Sheth, K.N.
Kamel, H.
Veltkamp, R.
Larsen, K.T.
Hofmeijer, J.
Kerkhoff, H.
Schreuder, F.H.B.M.
Shoamanesh, A.
Klijn, C.J.M.
Worp, H.B. van der
Al-Shahi Salman, R.
Stephen, J.
Tierney, J.F.
Lewis, Steff C.
Newby, D.E.
Parry-Jones, A.R.
White, P.M.
Connolly, S.J.
Benavente, O.R.
Dowlatshahi, D.
Cordonnier, C.
Viscoli, C.M.
Sheth, K.N.
Kamel, H.
Veltkamp, R.
Larsen, K.T.
Hofmeijer, J.
Kerkhoff, H.
Schreuder, F.H.B.M.
Shoamanesh, A.
Klijn, C.J.M.
Worp, H.B. van der
Source :
Lancet Neurology, 22, 12, pp. 1140-1149
Publication Year :
2023

Abstract

Contains fulltext : 300023.pdf (Publisher’s version ) (Open Access)<br />BACKGROUND: The safety and efficacy of oral anticoagulation for prevention of major adverse cardiovascular events in people with atrial fibrillation and spontaneous intracranial haemorrhage are uncertain. We planned to estimate the effects of starting versus avoiding oral anticoagulation in people with spontaneous intracranial haemorrhage and atrial fibrillation. METHODS: In this prospective meta-analysis, we searched bibliographic databases and trial registries using the strategies of a Cochrane systematic review (CD012144) on June 23, 2023. We included clinical trials if they were registered, randomised, and included participants with spontaneous intracranial haemorrhage and atrial fibrillation who were assigned to either start long-term use of any oral anticoagulant agent or avoid oral anticoagulation (ie, placebo, open control, another antithrombotic agent, or another intervention for the prevention of major adverse cardiovascular events). We assessed eligible trials using the Cochrane Risk of Bias tool. We sought data for individual participants who had not opted out of data sharing from chief investigators of completed trials, pending completion of ongoing trials in 2028. The primary outcome was any stroke or cardiovascular death. We used individual participant data to construct a Cox regression model of the time to the first occurrence of outcome events during follow-up in the intention-to-treat dataset supplied by each trial, followed by meta-analysis using a fixed-effect inverse-variance model to generate a pooled estimate of the hazard ratio (HR) with 95% CI. This study is registered with PROSPERO, CRD42021246133. FINDINGS: We identified four eligible trials; three were restricted to participants with atrial fibrillation and intracranial haemorrhage (SoSTART [NCT03153150], with 203 participants) or intracerebral haemorrhage (APACHE-AF [NCT02565693], with 101 participants, and NASPAF-ICH [NCT02998905], with 30 participants), and one included a subgroup of p<br />01 december 2023

Details

Database :
OAIster
Journal :
Lancet Neurology, 22, 12, pp. 1140-1149
Publication Type :
Electronic Resource
Accession number :
edsoai.on1414568733
Document Type :
Electronic Resource